Definium Therapeutics
DFTX
159 hedge funds and large institutions have $53.6M invested in Definium Therapeutics in 2022 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 33 increasing their positions, 41 reducing their positions, and 48 closing their positions.
180% more call options, than puts
Call options by funds: $4.31M | Put options by funds: $1.54M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.06% less ownership
Funds ownership: 0.82% → 0.76% (-0.06%)
10% less funds holding
Funds holding: 176 → 159 (-17)
20% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 41
26% less capital invested
Capital invested by funds: $72.4M → $53.6M (-$18.9M)
33% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 48
Top Buyers
Top Sellers
| 1 |
Millennium Management
New York
|
-$740K |
| 2 |
BlackRock
New York
|
-$730K |
| 3 |
LPL Financial
San Diego,
California
|
-$534K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$533K |
| 5 |
Two Sigma Investments
New York
|
-$516K |
DFTX Hedge Fund Activity: Q1 2022 in Review
159 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Definium Therapeutics (DFTX) for Q1 2022, worth a combined $53.6M — down 26% from $72.4M a quarter earlier.
Sellers outnumbered buyers: 48 funds closed out of DFTX and 32 opened new positions — a net loss of 16 holders — while 41 trimmed existing stakes and 33 added.
The largest buyer was State Street, adding an estimated $482K. The largest seller was Millennium Management, cutting an estimated $740K.
- 159 institutional investors held Definium Therapeutics (DFTX) as of Q1 2022, down from 176 in Q4 2021.
- Funds reported $53.6M of Definium Therapeutics stock for Q1 2022, down 26% quarter-over-quarter.
- 32 funds opened new Definium Therapeutics positions in Q1 2022 and 48 closed out, a net change of -16 holders.
- The largest Definium Therapeutics buyer in Q1 2022 was State Street, an estimated $482K added.
- The largest Definium Therapeutics seller in Q1 2022 was Millennium Management, an estimated $740K sold.
Based on aggregated 13F filings for Q1 2022.